Fiche centre
Irvine Clinical Research
Irvine — United States
Essais liés7clinical trials
VilleIrvinelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06544616
Essais cliniques associés
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| LY4405094 | Alzheimer | Phase 1 | NCT07787169 | A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease | NOT_YET_RECRUITING |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| LY4405094 | Alzheimer | Phase 1 | NCT07787182 | A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease | NOT_YET_RECRUITING |
| JNJ-64042056 | Alzheimer | Phase 2 | NCT06544616 | Reτain — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Donanemab | Alzheimer | Phase 2 | NCT07589595 | A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) | RECRUITING |
| LY3439539 | Alzheimer | Phase 1 | NCT07598370 | A Study of LY3439539 in Participants With Alzheimer's Disease | RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06976203 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | RECRUITING |